Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203138
Status:
COMPLETED
Last Update Posted:
2011-04-12
First Post:
2005-09-13
Brief Title:
Safety Tolerability and Effectiveness of Rasagiline Mesylate in Patients With Parkinsons Disease
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Multicenter Open-Label Phase III Study for the Safety Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients who completed the study TVP-1012232 are eligible to enter the extension study to continue their rasagiline therapy for their Parkinsons disease PD During this study the patients safety tolerability of rasagiline and effectiveness of this therapy will be monitored
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None